Starling (YC W22)

Starling Medical is a digital health device company based in Houston, Texas, founded in 2019. The company specializes in advanced urine diagnostic and remote patient monitoring technologies, focusing on innovative medical devices that address unmet clinical needs in urinary health. Their flagship product, UrinDx, is the first continuous at-home urine remote monitoring platform, designed to integrate seamlessly into patients' daily routines. This FDA-registered and Medicare-reimbursed device uses AI to passively screen for critical urinary biomarkers, enabling early detection of chronic health issues. Starling Medical's technology provides real-time urinary health insights directly to patients' smartphones, empowering them to adopt healthier habits. It also allows clinicians to monitor patient health remotely, enhancing clinical workflows. The company primarily serves patients with neurogenic bladder dysfunction and those prone to recurrent urinary tract infections, collaborating with clinical partners like Texas Children’s Hospital. Starling Medical aims to transform urinary health management through non-invasive, continuous monitoring solutions that improve patient independence and clinical care efficiency.

• Employees 14
• Founded 2019
• Annual Revenue $300000
• Total Funding $12290606